The FDA designates 2 biosimilars as interchangeable, enhancing access to treatments for inflammatory diseases and multiple ...

This case involves an appeal from Regeneron Pharmaceuticals, Inc.’s (Regeneron) efforts to prevent defendants from marketing biosimilar versions ...

The Seoul Central District Court ruled against Regeneron, which had sought to block Samsung Bioepis from producing and selling a biosimilar referencing the US firm’s Eylea, a blockbuster medicine used ...

Financial Hardship in Adolescent and Young Adult Oncology: The Need for Multidimensional and Multilevel Approaches The increased number and expanded utilization of biosimilars raise important ...

Fresenius Kabi also makes biosimilars, the generic forms of expensive biologic drugs such as Humira and Stelara. The United States is typically the last developed country where biosimilars appear on ...

Panelists discuss how NF1-associated plexiform neurofibromas can cause significant morbidity, including disfigurement, pain, and neurologic impairment, with the risk of malignant transformation ...

Retifanlimab-dlwr is approved for first-line treatment of advanced anal cancer, both in combination with chemotherapy and as monotherapy. Phase 3 trial results showed a 37% reduction in ...

Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter ...

Number 5: The authors of a review article on the future of ustekinumab biosimilars for treating Crohn disease (CD) discussed key challenges, including a lack of data in CD and opportunities to improve ...

which is an important part of our mission as a leading developer and manufacturer of biosimilars globally,” said Anil Okay, Chief Commercial Officer for Alvotech.

which is an important part of our mission as a leading developer and manufacturer of biosimilars globally. Selarsdi can now be substituted for the reference product without requiring a prescription ...

Ed Silverman, a senior writer and Pharmalot columnist at STAT, has been covering the pharmaceutical industry for nearly three decades. He is also the author of the morning Pharmalittle newsletter ...